KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Deferred Revenue: 2009-2016

Historic Current Deferred Revenue for Biomarin Pharmaceutical (BMRN) over the last 3 years, with Dec 2016 value amounting to $985,000.

  • Biomarin Pharmaceutical's Current Deferred Revenue was N/A to $17.4 million in Q3 2017 from the same period last year, while for Sep 2017 it was $17.4 million, marking a year-over-year change of. This contributed to the annual value of $985,000 for FY2016, which is N/A change from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Current Deferred Revenue stood at $985,000 for FY2016, which was up 188.01% from $342,000 recorded in FY2011.
  • Biomarin Pharmaceutical's Current Deferred Revenue's 5-year high stood at $985,000 during FY2016, with a 5-year trough of $985,000 in FY2016.
  • Over the past 1 years, Biomarin Pharmaceutical's median Current Deferred Revenue value was $985,000 (recorded in 2016), while the average stood at $985,000.